Richard B. Stead
Biotechonolgy and pharmaceutical
BioPharma Consulting?Services LLC
United States of America
Dr. Richard Stead has more than 20 years of experience in the biotechnology and pharmaceutical industry directing clinical trials, in- and out- licensing efforts, as well as preclinical research and development at Amgen and Immunex. Since 2002, he has worked as an independent consultant to biotechnology and pharmaceutical companies as well as investors in several therapeutic areas. He focuses on clinical and regulatory strategy for therapeutic product development as well as operational issues in executing clinical development programs. In 1988, Dr. Stead was recruited to Amgen as its first physician. He played significant roles in the clinical development, FDA approval and commercialization of Amgen's first two products, Epogen® and Neupogen®. In 1999, he joined Immunex as Vice President of Clinical Research and Development with responsibilities for both pipeline and marketed products for Oncology and Neurology. He negotiated the approval and post-marketing commitments for the approval of Novantrone® in multiple sclerosis with the FDA. Dr. Stead graduated from the University of Wisconsin and Stanford University School of Medicine. He completed his medical training at the Brigham and Women's Hospital and Harvard Medical School and a second post-doctoral fellowship at the National Cancer Institute.
He is interested in Clinical development